Literature DB >> 28838425

Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer.

Ali Hosni1, Caitlin McMullen2, Shao Hui Huang1, Wei Xu3, Jie Su3, Andrew Bayley1, Scott V Bratman1, John Cho1, Meredith Giuliani1, John Kim1, Jolie Ringash1, John Waldron1, Anna Spreafico4, Ilan Weinreb5, John R de Almeida2, Dale H Brown2, Jonathan C Irish2, Brian O'Sullivan1, David P Goldstein2, Andrew Hope6.   

Abstract

BACKGROUND: We aimed to investigate the impact of lymph node ratio (LNR, number of positive nodes/total number of excised nodes) on regional-only-failure, distant-only-failure and overall survival (OS) in oral squamous cell carcinoma (OSCC).
METHODS: Retrospective review of pN0-2 OSCC-patients (1994-2012) treated with curative-surgery with neck dissection±postoperative radiotherapy (PORT)±concurrent chemotherapy. LNR was subjected to multivariable analysis (MVA) of regional-only-failure, distant-only-failure and OS.
RESULTS: Overall 914 patients were identified; median follow-up: 51months (1-189); pN0: 482 (52.7%), pN1: 128 (14%), pN2a: 6 (0.7%); pN2b: 225 (24.6%); pN2c: 73 (8%); median number of dissected nodes: 36 (6-125); median number of pN+: 2 (1-49); median LNR for pN+ patients: 6%; extranodal extension: 187 (20.5%). Bilateral neck dissection: 368 (40.3%); PORT: 452 (49.5%); and concurrent chemotherapy: 80 (8.8%). High grade, lymphovascular invasion perineural invasion and pT3-4 were associated with high LNR. On MVA, LNR was associated with regional-only-failure (HR=1.06; 95%CI: 1.04-1.08; p<0.001), distant-only-failure (HR=1.03; 95%CI: 1.02-1.05; p=0.004) and lower OS (HR=1.03; 95%CI: 1.02-1.05; p<0.001). Similarly, in pN2-subgroup: LNR was associated with regional-only-failure (HR=1.04; 95%CI: 1.02-1.06; p<0.001), distant-only-failure (HR=1.03; 95%CI: 1.01-1.06; p=0.045) and lower OS (HR=1.03; 95%CI: 1.02-1.04; p<0.001).
CONCLUSION: High LNR is associated with higher regional-only-failure/distant-only-failure and lower OS. LNR should be assessed in future prospective trials for selection of adjuvant therapy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Distant metastases; Lymph node ratio; Oral cancer; Prognostic factors; Regional failure

Mesh:

Year:  2017        PMID: 28838425     DOI: 10.1016/j.radonc.2017.06.018

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Towards an Improved Pathological Node Classification for Prognostic Stratification of Patients With Oral Cavity Squamous Cell Carcinoma: Results From a Nationwide Registry Study.

Authors:  Chung-Jan Kang; Yu-Wen Wen; Shu-Ru Lee; Shu-Hang Ng; Chi-Ying Tsai; Li-Yu Lee; Ying-Hsia Chu; Chien-Yu Lin; Kang-Hsing Fan; Hung-Ming Wang; Chia-Hsun Hsieh; Chih-Hua Yeh; Chih-Hung Lin; Chung-Kan Tsao; Tuan-Jen Fang; Shiang-Fu Huang; Li-Ang Lee; Ku-Hao Fang; Yu-Chien Wang; Wan-Ni Lin; Li-Jen Hsin; Tzu-Chen Yen; Nai-Ming Cheng; Chun-Ta Liao
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

Review 2.  Distant metastasis from oral cavity-correlation between histopathology results and primary site.

Authors:  Yuka Uchiyama; Tadashi Sasai; Atsutoshi Nakatani; Hiroaki Shimamoto; Tomomi Tsujimoto; Sven Kreiborg; Shumei Murakami
Journal:  Oral Radiol       Date:  2020-05-28       Impact factor: 1.852

3.  SNHG1/miR-145-5p/KLF5 Axis Participates in Regulating the Proliferation and Migration of Oral Squamous Cell Cancer.

Authors:  Haiyan Xin; Ziyan Feng; Chao Yao
Journal:  J Healthc Eng       Date:  2022-03-03       Impact factor: 2.682

4.  Diversity of the Origin of Cancer Stem Cells in Oral Squamous Cell Carcinoma and Its Clinical Implications.

Authors:  Chonji Fukumoto; Daisuke Uchida; Hitoshi Kawamata
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

5.  Silencing of LINC00284 inhibits cell proliferation and migration in oral squamous cell carcinoma by the miR-211-3p/MAFG axis and FUS/KAZN axis.

Authors:  Dayong Yan; Fuhua Wu; Caixia Peng; Mei Wang
Journal:  Cancer Biol Ther       Date:  2021-02-22       Impact factor: 4.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.